EBITDA Margin (Annual)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

Vertex Pharmaceuticals Incorporated (VRTX) had EBITDA Margin of 40.66% for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$9.87B
Net Income	$3.62B
Cost of Goods Sold	$1.26B
Gross Profit	$8.61B
Operating Expenses	$6.04B
Operating Income	$3.83B
Non-Operating Income/Expense	$547.80M
Pre-Tax Income	$4.38B
Normalized Pre-Tax Income	$4.38B
Income after Taxes	$3.62B
Income from Continuous Operations	$3.62B
Consolidated Net Income/Loss	$3.62B
Normalized Income after Taxes	$3.62B
EBIT	$3.83B
EBITDA	$4.01B
Weighted-Average Shares Outstanding (Basic)	257.70M
Weighted-Average Shares Outstanding (Diluted)	260.50M
Earnings per Share (EPS) (Basic)	$14.05
Earnings per Share (EPS) (Diluted)	$13.89
Balance Sheet Financials
Current Assets	$14.14B
Property, Plant, and Equipment	$1.16B
Long-Term Assets	$8.59B
Total Assets	$22.73B
Current Liabilities	$3.55B
Long-Term Debt	$376.10M
Long-Term Liabilities	$1.60B
Total Liabilities	$5.15B
Common Equity	$17.58B
Tangible Shareholders Equity	$15.65B
Shareholders Equity	$17.58B
Common Shares Outstanding	257.69M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$3.54B
Cash Flow from Investing Activities	$-3.14B
Cash Flow from Financial Activities	$-562.20M
Beginning Cash	$10.51B
End Cash	$10.37B
Increase/Decrease in Cash	$-139.70M
Stock-Based Compensation	$581.20M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.99
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.02
Debt to Equity Ratio	0.02
Gross Margin	87.21%
Operating Margin	38.83%
EBIT Margin	38.83%
EBITDA Margin	40.66%
Pre-Tax Profit Margin	44.38%
Profit Margin	36.68%
Free Cash Flow	$3.34B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.43
Inventory Turnover	1.71
Receiveable Turnover	6.31
Days Sales in Receivables	57.82
Return on Equity	20.59%
Return on Tangible Equity	23.12%
Return on Assets	15.92%
Return on Investments	20.16%
Book Value Per Share	$68.22
Free Cash Flow per Share	$12.81
Operating Cash Flow per Share	$13.58

Data from Zacks Investment Research, Inc.